Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.58 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.53 |
| ▸ | ABL1 | P00519 | 1/20 | 0.53 |
| ▸ | PRKCG | P05129 | 1/20 | 0.53 |
| ▸ | PRKCB | P05771 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 1/20 | 0.53 |
| ▸ | CDK4 | P11802 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | PRKACA | P17612 | 1/20 | 0.53 |
| ▸ | PRKACG | P22612 | 1/20 | 0.53 |
| ▸ | PRKACB | P22694 | 1/20 | 0.53 |
| ▸ | CCND1 | P24385 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14259877 | 0.86 | NR4A2 (0.51) | PARP1SIRT2MAPK1IMPDH2NR4A2 | |
| SCHEMBL13347974 | 0.86 | KDM4E (0.52) | PARP1SIRT2MAPK1IMPDH2NR4A2 | |
| 3-Phenylindole SCHEMBL29609072 | 0.84 | IMPDH2 (0.71) | PARP1SIRT2MAPK1IMPDH2NR4A2 | |
| 3-Phenylindole SCHEMBL84056 | 0.84 | IMPDH2 (0.71) | PARP1SIRT2MAPK1IMPDH2NR4A2 | |
| SCHEMBL1239238 | 0.82 | GSK3B (0.59) | MAPK1IMPDH2NR4A2PIM1CDK4 | |
| SCHEMBL7261295 | 0.82 | CDK4 (0.60) | SIRT2NR4A2CDK4CCND1SMN1; SMN2 | |
| SCHEMBL13312371 | 0.80 | IMPDH2 (0.55) | PARP1IMPDH2PRKD3CCNB2CCNE2 | |
| SCHEMBL16459160 | 0.80 | CAMK2D (0.49) | PARP1IMPDH2NR4A2PRKD3PRKCG | |
| SCHEMBL28377762 | 0.77 | NR4A2 (0.81) | SIRT2MAPK1IMPDH2NR4A2PRKD3 | |
| SCHEMBL7262282 | 0.76 | ABCG2 (0.55) | NR4A2PRKD3ABL1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2064185-B1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INT (ES) | 2011-06-08 | — | — | EP | disclosed |
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNACIONAL, S.A. (ES) | 2010-07-01 | — | — | US | disclosed |
| EP-1886996-A1 | 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2008-02-13 | — | — | EP | disclosed |
| US-6645983-B1 | Heterocyclic imines such as 3-(4-methoxyphenyl)-1,4-dihydro-4 -quinolinone, used as anticarcinogenic agents having cytolysis efficiency; side effect reduction | LABORATOIRE L. LAFON (FR) | 2003-11-11 | — | — | US | disclosed |
| EP-1202971-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES | LABORATOIRE L. LAFON (FR) | 2002-05-08 | — | — | EP | disclosed |
| WO-2002022074-A2 | USE OF 2- AND 4- QUINOLONES FOR INHIBITING INTIMAL NEO-PROLIFERATION | LABORATOIRE L. LAFON (FR) | 2002-03-21 | — | — | WO | disclosed |
| WO-2001012607-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING 4-QUINOLONES FOR TREATING CANCERS | LABORATOIRE L. LAFON (FR) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168099-A1 | 1H-QUINOLIN-4-ONE COMPOUNDS, WITH AFFINITY FOR THE GABA RECEPTOR, PROCESSES, USES AND COMPOSITIONS | GABRA1, GABRA4, GABRA2 | PARP1 2909/4885SIRT2 2012/4885MAPK1 2959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.